Thank goodness…just in time…I'm in line…
7 May 2026
Korea University and Moderna have been working on mRNA hantavirus vaccine since 2023
Korea University's Vaccine Innovation Center and US biotech firm Moderna (formerly ModeRNA Therapeutics), made world-famous by its multibillion-dollar Covid-19 vaccine profits.
Korea University’s Vaccine Innovation Center (VIC-K) and US biotech firm Moderna (formerly ModeRNA Therapeutics), made world-famous by its multibillion-dollar Covid-19 vaccine profits, have been jointly developing an mRNA-based hantavirus vaccine since signing a research and development agreement in September 2023, with the candidate now awaiting funding to begin human clinical trials.
The deal was struck under Moderna’s mRNA Access initiative, a programme that supplies preclinical mRNA vaccine candidates to academic teams working on emerging or neglected infectious diseases. The two sides had begun exploring possible collaboration as early as 2021.
A research team led by Professor Park Man-sung of Korea University College of Medicine’s microbiology department confirmed in February 2025 that experimental doses prevented hantavirus infection in mice, according to Seoul Economic Daily.
https://brusselssignal.eu/2026/05/korea-university-and-moderna-have-been-working-on-mrna-hantavirus-vaccine-since-2023/